Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · Real-Time Price · USD
1.640
-0.020 (-1.20%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Fortress Biotech Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Fortress Biotech stock have an average target of 21, with a low estimate of 16 and a high estimate of 26. The average target predicts an increase of 1,180.49% from the current stock price of 1.64.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 11, 2025.
Analyst Ratings
The average analyst rating for Fortress Biotech stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Strong Buy Reiterates $15 → $16 | Strong Buy | Reiterates | $15 → $16 | +875.61% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $24 → $26 | Strong Buy | Maintains | $24 → $26 | +1,485.37% | Nov 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $24 | Strong Buy | Reiterates | $24 | +1,363.41% | Jul 19, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jun 20, 2024 |
| Roth MKM | Roth MKM | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +509.76% | May 16, 2024 |
Financial Forecast
Revenue This Year
94.13M
from 57.68M
Increased by 63.20%
Revenue Next Year
156.91M
from 94.13M
Increased by 66.70%
EPS This Year
-1.64
from -2.69
EPS Next Year
-1.03
from -1.64
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 137.3M | 165.0M | 208.7M |
| Avg | 94.1M | 156.9M | 202.8M |
| Low | 70.9M | 147.6M | 194.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 138.1% | 75.3% | 33.0% |
| Avg | 63.2% | 66.7% | 29.2% |
| Low | 22.9% | 56.8% | 24.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.45 | -0.99 | -0.48 |
| Avg | -1.64 | -1.03 | -0.47 |
| Low | -1.76 | -1.05 | -0.45 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.